In this paper there will be a company valuation of Genmab A/S, to disclose if the market value on their shares has been overvalued. The analysis will use methods from Marketing & Sales, and Finance & Accounting. It will be PEST, Porter’s Five Forces and SWOT, and the DCF-model from absolute values. The results estimated an intrinsic value of Genmab, 39.145,490 million DDK. Furthermore, the stock price was estimated at 648, while the market value was 1173. It was therefore concluded, Genmab was overvalued on the market, but from the marketing and finance analysis, a long-term investment could potentially be profitable.
|Uddannelser||Erhvervsøkonomi, (Bachelor/kandidatuddannelse) Bachelor|
|Udgivelsesdato||19 dec. 2017|